

DGSE COMPANIES INC  
Form SC 13D/A  
November 21, 2014

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

SCHEDULE 13D/A  
Rule 13d-101

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO  
§ 240.13d-2(a)

(Amendment No. 22)

**DGSE COMPANIES, INC.**  
(Name of Issuer)

**Common Stock, par value \$0.01 per share**  
(Title of Class of Securities)

**23323G106**  
(CUSIP Number)

**Dr. L. S. Smith**

**519 Interstate 30, Suite 243**

**Rockwall, Texas 75087**

**(972) 484-3662**  
(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

**November 12, 2014**  
(Date of Event Which Requires Filing of this Statement)

Edgar Filing: DGSE COMPANIES INC - Form SC 13D/A

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box “”.

*Note.* Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. *See* § 240.13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 23323G106 Schedule 13D/A Page 2 of 5

**1** NAMES OF REPORTING PERSONS

**Dr. L. S. Smith**

CHECK

THE

APPROPRIATE

**2** BOX IF A (a) "

MEMBER

OF A (b) "

GROUP

(see instructions)

SEC USE ONLY

**3**

SOURCE OF FUNDS

(see instructions)

**4**

**N/A**

CHECK IF

DISCLOSURE

OF LEGAL

PROCEEDINGS

**5** IS  x

REQUIRED

PURSUANT

TO ITEM

2(d) or 2 (e)

CITIZENSHIP OR

PLACE OF

**6** ORGANIZATION

**United States**

NUMBER OF SOLE VOTING SHARES **7** POWER

BENEFICIALLY **1,211,797**

**8** SHARED VOTING OWNED BY POWER EACH

REPORTING **0**  
SOLE  
PERSON WITH **9** DISPOSITIVE  
POWER

**1,211,797**  
**10** SHARED  
DISPOSITIVE  
POWER

**0**  
AGGREGATE  
AMOUNT  
**11** BENEFICIALLY  
OWNED BY EACH  
REPORTING PERSON

**1,211,797**  
CHECK IF  
THE  
AGGREGATE  
AMOUNT  
IN ROW

**12** (11) ..  
EXCLUDES  
CERTAIN  
SHARES  
(see  
instructions)  
PERCENT OF CLASS  
REPRESENTED BY  
**13** AMOUNT IN ROW 11

**9.9%**  
TYPE OF REPORTING  
PERSON (see  
**14.** instructions)

**IN**

CUSIP No. 23323G106 Schedule 13D/A Page 3 of 5

**Item 1. Security and Issuer.**

This statement relates to the common stock, par value \$0.01 per share (the “**Common Stock**”), of DGSE Companies, Inc., a Nevada corporation (the “**Issuer**”), whose principal executive office is located at 15850 Dallas Parkway, Suite 140, Dallas, Texas 75248.

**Item 2. Identity and Background.**

(a) Dr. L. S. Smith, an individual (“**Dr. Smith**”).

(b) M19 Interstate 30, Suite 243, Rockwall, Texas 75087.

(c) Not applicable.

(d) During the last five years, Dr. Smith has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) Dr. Smith is subject to an order by the Securities and Exchange Commission (the “**Commission**”) dated November 12, 2014 which arose out of financial reporting, books and records, and internal controls violations by the Issuer and its former Chief Financial Officer that occurred during Dr. Smith’s tenure as the Issuer’s Chief Executive Officer. As a result of these violations, the Issuer restated certain financial statements. The Commission did not allege that Dr. Smith participated in the wrongful conduct. Dr. Smith had not, however, reimbursed the Issuer for incentive compensation and stock sale profits he received during the relevant period, as required by Section 304(a) of the Sarbanes-Oxley Act of 2002 (“**Sarbanes-Oxley**”).

Accordingly, the Commission ordered that (i) pursuant to Section 21C of the Exchange Act, Dr. Smith cease and desist from committing or causing any violations and any future violations of Sarbanes-Oxley Section 304(a) and (ii) Dr. Smith shall reimburse the Issuer a total of \$106,250 and 59,738 shares of DGSE stock pursuant to Section 304(a) of Sarbanes-Oxley.

(f) Dr. Smith is a citizen of the United States.

**Item 3. Source and Amount of Funds or Other Consideration.**

Not applicable.

**Item 4. Purpose of Transaction.**

Not applicable.

**Item 5. Interest in Securities of Issuer.**

(a) As of the date of this report, Dr. Smith beneficially owns 1,211,797 shares of the Issuer's Common Stock, which, in the aggregate, represents 9.9% of the currently outstanding shares of the Issuer's Common Stock. The foregoing calculation of percentage ownership is based on 12,223,584 shares of Common Stock outstanding, as reported in the Issuer's most recent Form 10-Q filed November 13, 2014.

(b) Dr. Smith has the sole power to vote or to direct the vote and sole power to dispose or direct the disposition with respect to 1,211,797 shares of the Issuer's Common Stock.

**CUSIP No. 23323G106 Schedule 13D/A Page 4 of 5**

(c) Not applicable.

(d) Dr. Smith confirms that he is not aware of any other person with the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any of the shares of common stock of the Issuer beneficially owned by him.

(e) Not applicable.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Not applicable.

**Item 7. Materials to be Filed as Exhibits.**

Not applicable.

**CUSIP No. 23323G106 Schedule 13D/A Page 5 of 5**

**SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Dr. L. S. Smith**

/s/ Dr. L.S. Smith  
Dr. L. S. Smith

Date: November 21, 2014